21,371 Shares in Tharimmune, Inc. (NASDAQ:THAR) Purchased by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the fourth quarter, Holdings Channel.com reports. The firm purchased 21,371 shares of the company’s stock, valued at approximately $44,000.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw assumed coverage on Tharimmune in a research report on Friday, December 6th. They issued a “buy” rating and a $17.00 target price for the company.

Tharimmune Stock Performance

Shares of NASDAQ:THAR opened at $1.28 on Wednesday. The company’s fifty day moving average is $1.69 and its two-hundred day moving average is $2.07. Tharimmune, Inc. has a 1-year low of $1.20 and a 1-year high of $7.46. The stock has a market capitalization of $2.48 million, a price-to-earnings ratio of -0.13 and a beta of 1.28.

Tharimmune (NASDAQ:THAR) last posted its earnings results on Tuesday, March 25th. The company reported ($2.02) EPS for the quarter.

Tharimmune Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).